DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/073300/osteoarthritis_oa) has announced the addition of GlobalData's new report "Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global osteoarthritis therapeutics market.
GlobalData estimates that the global OA therapeutics market was worth $4.4 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 3.8% to reach $5.9 billion by 2018. The current treatment options for OA offer only symptomatic relief and are primarily dominated by generics. There are no disease modifying osteoarthritis drugs (DMOAD) currently approved in the OA therapeutics market and the late stage pipeline also lacks DMOADs except SMC021. Owing to all the above factors the OA therapeutics market is expected to show slow growth till 2018.
Scope
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing analysis of the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for osteoarthritis fall under major therapeutic classes such as stem cell therapy, cyclooxygenase (COX) inhibitor, cathepsin inhibitors, opioid receptor agonist, anti-nerve growth factor (NGF) inhibitor, transient receptor potential vanilloid-1 (TRPV-1) antagonists, cyclooxygenase inhibiting nitric oxide donor, phosphodiesterase inhibitor and calcitonin receptor agonist.
- Analysis of current and future competition in the global osteoarthritis market is provided.
- Insightful review of the key industry drivers, restraints and challenges.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis therapeutics market.
- Analysis of key recent licensing and partnership agreements.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis therapeutics market in future.
- Formulate effective sales and marketing strategies.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies.
Companies Mentioned
- BioDelivery Sciences International
- Cephalon Inc
- Iroko Pharmaceuticals
- LLC
- Novartis AG
- SantoSolve AS
- Winston Pharmaceuticals, Inc
For more information visit http://www.researchandmarkets.com/research/073300/osteoarthritis_oa